During the past decade, Western Carolina Retinal Associate PA conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 13 clinical trials were completed, i.e. on average, 44.8% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 12 clinical trials were completed. i.e. 70.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Western Carolina Retinal Associate PA" #1 sponsor was "Hoffmann-La Roche" with 12 trials, followed by "Genentech, Inc." with 7 trials sponsored, "Apellis Pharmaceuticals, Inc." with 2 trials sponsored, "Clearside Biomedical, Inc." with 2 trials sponsored and "Jaeb Center for Health Research" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Western Carolina Retinal Associate PA" #1 collaborator was "National Eye Institute (NEI)" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "National Center for Complementary and Integrative Health (NCCIH)" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Western Carolina Retinal Associate PA" are "Geographic Atrophy" (13 trials), "Diabetic Macular Edema" (8 trials), "Macular Degeneration" (7 trials), "Macular Degeneration, Age-Related" (2 trials) and "Neovascular Age-related Macular Degeneration" (2 trials). Many other conditions were trialed in "Western Carolina Retinal Associate PA" in a lesser frequency.

Most popular intervention types in "Western Carolina Retinal Associate PA" are "Drug" (34 trials), "Other" (11 trials), "Procedure" (3 trials), "Biological" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (9 trials), "Faricimab" (6 trials), "Lampalizumab" (4 trials), "Ranibizumab" (4 trials) and "Aflibercept" (3 trials). Other intervention names were less common.

The vast majority of trials in "Western Carolina Retinal Associate PA" are 36 trials for "All" genders.

Currently, there are NaN active trials in "Western Carolina Retinal Associate PA". undefined are not yet recruiting, 2 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Western Carolina Retinal Associate PA, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Western Carolina Retinal Associate PA, 6 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".